{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:20:53Z","timestamp":1771708853222,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1124\/jpet.121.000744","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:40:14Z","timestamp":1627501214000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nuclear Factor Erythroid 2\u2013Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression"],"prefix":"10.1016","volume":"379","author":[{"given":"Ryotaro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000744_bib1","doi-asserted-by":"crossref","first-page":"e00099-e20","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.121.000744_bib2","doi-asserted-by":"crossref","first-page":"111962","DOI":"10.1016\/j.ejmech.2019.111962","article-title":"Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents","volume":"187","author":"Dinavahi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1124\/jpet.121.000744_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/antiox6030052","article-title":"Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1 and sensitizes to 5-FU in pancreatic cancer cells","volume":"6","author":"Duong","year":"2017","journal-title":"Antioxidants"},{"key":"10.1124\/jpet.121.000744_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jcp.22781","article-title":"The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2","volume":"227","author":"Hamada","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1124\/jpet.121.000744_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/carcin\/bgx043","article-title":"Nrf2 promotes mutant K-ras\/p53-driven pancreatic carcinogenesis","volume":"38","author":"Hamada","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1124\/jpet.121.000744_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.121.000744_bib7","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1101\/gad.943001","article-title":"Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras","volume":"15","author":"Jackson","year":"2001","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.121.000744_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.121.000744_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.06.004","article-title":"Nrf2 regulates the alternative first exons of CD36 in macrophages through specific antioxidant response elements","volume":"477","author":"Maruyama","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/jpet.121.000744_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.121.000744_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","article-title":"Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines","volume":"55","author":"Okusaka","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1124\/jpet.121.000744_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","article-title":"Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome","volume":"119","author":"Olive","year":"2004","journal-title":"Cell"},{"key":"10.1124\/jpet.121.000744_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ng1032","article-title":"Microarray data normalization and transformation","volume":"32","author":"Quackenbush","year":"2002","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.121.000744_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cas.14278","article-title":"Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites","volume":"111","author":"Saigusa","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1124\/jpet.121.000744_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4161\/15384047.2014.986967","article-title":"Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors","volume":"16","author":"Samulitis","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1124\/jpet.121.000744_bib16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.121.000744_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cancers13010046","article-title":"The KEAP1-NRF2 system as a molecular target of cancer treatment","volume":"13","author":"Taguchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1124\/jpet.121.000744_bib18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2016.12.041","article-title":"Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation","volume":"103","author":"Tsuchida","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/jpet.121.000744_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11010-020-03729-3","article-title":"Exosomes carrying ALDOA and ALDH3A1 from irradiated lung cancer cells enhance migration and invasion of recipients by accelerating glycolysis","volume":"469","author":"Wang","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/jpet.121.000744_bib20","first-page":"3784","article-title":"Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1124\/jpet.121.000744_bib21","doi-asserted-by":"crossref","first-page":"D1144","DOI":"10.1093\/nar\/gkr1013","article-title":"PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update","volume":"40","author":"Wang","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.121.000744_bib22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00023.2017","article-title":"The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis","volume":"98","author":"Yamamoto","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.121.000744_bib23","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3892\/mmr.2017.6699","article-title":"Prognosis genes in gastric adenocarcinoma identified by cross talk genes in disease-related pathways","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Med Rep"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524271184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:03:34Z","timestamp":1739973814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524271184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0022356524271184"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000744","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear Factor Erythroid 2\u2013Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}